1-5 of 5
Tanya Granston
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2)

Ruben A. Mesa, MD FACP, Francisco Cervantes, MD PhD, Claire N. Harrison, MD DM, FRCP, PRCPath, Adam J. Mead, MD PhD, Alessandro M. Vannucchi, MD, Srdan Verstovsek, MD PhD, Lixia Wang, PhD, Tanya Granston, PhD, John Mascarenhas, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4281.
https://doi.org/10.1182/blood-2018-99-114779
Published: 2018
Journal Articles

Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl

John Mascarenhas, Ronald Hoffman, Moshe Talpaz, Aaron T. Gerds, Brady Stein, Vikas Gupta, Anita Szoke, Mark Drummond, Alexander Pristupa, Tanya Granston, Robert Daly, James P. Dean, Suliman Al-Fayoumi, Jennifer A. Callahan, Jack W. Singer, Jason Gotlib, Catriona Jamieson, Claire Harrison, Ruben Mesa, Srdan Verstovsek
Journal: Blood
Blood (2016) 128 (22): LBA-5.
https://doi.org/10.1182/blood.V128.22.LBA-5.LBA-5
Published: 2016
Journal Articles

Relationship Between Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQoL) and Efficacy in Patients with Myelofibrosis in the Phase III Persist-1 Trial of Pacritinib Vs. Best Available Therapy (BAT)

Ruben A. Mesa, Claire N. Harrison, Francisco Cervantes, James P. Dean, Lixia Wang, Tanya Granston, Yoojung Yang, Alessandro M. Vannucchi, Adam Mead
Journal: Blood
Blood (2015) 126 (23): 1609.
https://doi.org/10.1182/blood.V126.23.1609.1609
Published: 2015
Journal Articles

Analysis of Outcomes By Patient Subgroups in Patients with Myelofibrosis Treated with Pacritinib Vs Best Available Therapy (BAT) in the Phase III Persist-1 Trial

Alessandro M. Vannucchi, Ruben A. Mesa, Francisco Cervantes, Ritam Prasad, Janos Jakucs, Anna Elinder, Christian Recher, MDPhD, Peter A. te Boekhorst, Steven Knapper, Tim Somervaille, James P. Dean, Tanya Granston, Adam Mead, Claire N. Harrison
Journal: Blood
Blood (2015) 126 (23): 58.
https://doi.org/10.1182/blood.V126.23.58.58
Published: 2015
Journal Articles

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

Clinical Trials & Observations
Rami S. Komrokji, John F. Seymour, Andrew W. Roberts, Martha Wadleigh, L. Bik To, Robyn Scherber, Elyce Turba, Andrew Dorr, Joy Zhu, Lixia Wang, Tanya Granston, Mary S. Campbell, Ruben A. Mesa
Journal: Blood
Blood (2015) 125 (17): 2649–2655.
https://doi.org/10.1182/blood-2013-02-484832
Published: 2015
Includes: Supplemental data